Accounting for the increase in NSAID expenditure: Substitution or leakage?

Cost Effectiveness and Resource Allocation

Volumn 4, Issue , 2006, Pages

  Barton, Garry R ^a   Avery, Anthony J ^a   Whynes, David K ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ARTHRITIS; ARTICLE; CORRELATION ANALYSIS; DRUG COST; GASTROINTESTINAL SYMPTOM; HUMAN; POPULATION RESEARCH; PRESCRIPTION;

EID: 33746076672     PISSN: 14787547     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-4-9     Document Type: Article

References (30)

1. Health and Social Care Information Centre: Prescription Cost Analysis: 2004. London, Health and Social Care Information Centre; 2005.
2. Hawkey CJ, Langman MJ: Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 2003, 52(4):600-608.
3. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C: Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004, 19(11):1189-1198.
4. NICE appraisal team: The clinical effectiveness and cost-effectiveness of celecoxib, rofecoxib, meloxicam, and etodolac (COX-11 inhibitors) for rheumatiod arthritis. London, NICE; 2000.
5. National Institute of Health and Clinical Excellence (NICE): Guidance on the use of Cox 11 selective inhibitors. Technology Appraisal No. 27. London, NICE, 2001.
6. O'Brien BJ: Cost-effective prescribing: trying to hit the target in Ontario and Australia. Australian Prescriber 2002, 26:128-130.
7. Lopert R, Henry D: The Pharmaceutical Benefits Scheme: economic evaluation works ... but is not a panacea. Australian Prescriber 2002, 25:126-127.
8. Pillans PI, Kubler PA, Radford JM, Overland V: Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 2000, 172:16-18.
9. National Institute of Health and Clinical Excellence (NICE): Guidance on the use of trastuzumb for the treatment of advanced breast cancer. London, NICE; 2002.
10. Collier J: Panorama: Herceptin: Wanting the Wonder. BMJ 2006, 332:368.
11. Maetzel A, Krahn M, Naglie G: The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Arthritis Rheum 2003, 49(3):283-292.
12. Spiegel BM, Targownik L, Dulai GS, Gralnek IM: The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 2003, 138(10):795-806.
13. Department of Health: Prescription Cost Analysis: England 1998. London, Department of Health; 1999.
14. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. JAMA 2000, 284(10):1247-1255.
15. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, Vigor Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343(21):1520-1528.
16. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E, The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2000, 43(2):370-377.
17. Hawkey CJ, Laine L, Harper SE, Quan HU, Bolognese JA, Mortensen E, Rofecoxib Osteoarthritis Endoscopy Multinational Study Group: Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. Aliment Pharmacol Ther 2001, 15(10):1593-1601.
18. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J, Rofecoxib Rheumatoid Arthritis Endoscopy Study Group: Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003, 52(6):820-826.
19. Joshua FF, Oakley SP, Major GA: Impact of selective cyclooxygenase-2 inhibitors an anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Intern Med J 2004, 34(4):153-161.
20. Dai C, Stafford RS, Alexander GC: National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 2005, 165(2):171-177.
21. Kuehn BM: FDA panel: keep COX-2 drugs on market: black box for COX-2 labels, caution urged for all NSAIDs. JAMA 2005, 293(13):1571-1572.
22. Bogle SM, Harris CM: Measuring prescribing: the shortcomings of the item. BMJ 1994, 308(6929):637-640.
23. Harkness EF, Macfarlane GJ, Silman AJ, McBeth J: Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. Rheumatology (Oxford) 2005, 44:890-895.
24. Department of Health: Prescription Cost Analysis: England 1999. London, Department of Health; 2000.
25. Singh D: Merck withdraws arthritis drug worldwide. BMJ 2004, 329(7470):816.
26. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352(11):1092-1102.
27. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365(9458):475-481.
28. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352(11):1071-1080.
29. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz AJ, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators: The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005, 165:161-168.
30. Lenzer J: FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 2005, 330(7489):440.